Summary
Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billion, an increase of 7.5% compared to the same period in the prior year. Net income also saw a significant rise, up 25% to $3.49 billion. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent. Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.
Financial Highlights
46 data points| Revenue | $3.72B |
| R&D Expenses | $1.27B |
| SG&A Expenses | $714.40M |
| Operating Expenses | $2.54B |
| Operating Income | $1.18B |
| Net Income | $1.34B |
| EPS (Basic) | $12.40 |
| EPS (Diluted) | $11.54 |
| Shares Outstanding (Basic) | 108.10M |
| Shares Outstanding (Diluted) | 116.20M |
Key Highlights
- 1Total revenues for the nine months ended September 30, 2024, increased by 7.5% to $10.41 billion, driven by strong product sales and collaboration revenues.
- 2Net income for the nine months ended September 30, 2024, rose by 25% to $3.49 billion, resulting in diluted earnings per share of $30.23.
- 3Dupixent and Kevzara collaboration revenue experienced a significant increase of 23%, reflecting strong global sales performance.
- 4EYLEA HD and EYLEA U.S. net product sales increased by 3.1% to $4.47 billion for the nine months ended September 30, 2024, driven by the launch of EYLEA HD.
- 5Research and development expenses increased by 14% to $3.72 billion for the nine months ended September 30, 2024, indicating continued investment in pipeline development.
- 6The company repurchased $1.64 billion of its common stock during the nine months ended September 30, 2024, under its share repurchase program.
- 7Regeneron maintained a strong liquidity position with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities as of September 30, 2024.